Journal of Antimicrobial Chemotherapy, Vol 41, 301-305, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy
P Russell, SM Eley, M Green, AJ Stagg, RR Taylor, M Nelson, RJ Beedham, DL Bell, D Rogers, D Whittington and RW Titball
The efficacies of ciprofloxacin and doxycycline prophylaxis and therapy
were assessed against experimental pneumonic plague infections induced by
two strains of Yersinia pestis in a mouse model. When exposed to an aerosol
of Y. pestis strain GB, containing 8.39 x 10(5) +/- 4.17 x 10(4) cfu, the
retained dose was 7.3 x 10(3) +/- 2.3 x 10(3) cfu. When exposed to an
aerosol of Y. pestis strain CO-92, containing 1.86 x 10(5) +/- 7.4 x 10(3)
cfu, the retained dose was 3.4 x 10(4) +/- 2.6 x 10(3) cfu. Both strains
resulted in a respiratory and systemic infection closely resembling human
pneumonic plague. Ciprofloxacin prophylaxis and therapy was successful
against both strains for up to 24 h after challenge, but not after 48 h.
Both doxycycline prophylaxis and therapy regimens were ineffective against
both strains, although strain CO-92 was more susceptible in vitro to
doxycycline than strain GB and supra-MIC levels were achieved in the serum
and lungs of the animal.
ORIGINAL ARTICLES
Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection
CBD Porton Down, Salisbury, Wiltshire, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. J. Thomas, D. Webber, A. Collinge, A. J. Stagg, S. C. Bailey, A. Nunez, A. Gates, P. N. Jayasekera, R. R. Taylor, S. Eley, et al. Different Pathologies but Equal Levels of Responsiveness to the Recombinant F1 and V Antigen Vaccine and Ciprofloxacin in a Murine Model of Plague Caused by Small- and Large-Particle Aerosols Infect. Immun., April 1, 2009; 77(4): 1315 - 1323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Louie, M. R. Deziel, W. Liu, and G. L. Drusano Impact of Resistance Selection and Mutant Growth Fitness on the Relative Efficacies of Streptomycin and Levofloxacin for Plague Therapy Antimicrob. Agents Chemother., August 1, 2007; 51(8): 2661 - 2667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Anisimov and K. K. Amoako Treatment of plague: promising alternatives to antibiotics. J. Med. Microbiol., November 1, 2006; 55(Pt 11): 1461 - 1475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Thomas and T. Brooks Attachment of Yersinia pestis to human respiratory cell lines is inhibited by certain oligosaccharides. J. Med. Microbiol., March 1, 2006; 55(Pt 3): 309 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nelson, J. L Prior, M S. Lever, H. E Jones, T. P Atkins, and R. W Titball Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis J. Med. Microbiol., December 1, 2004; 53(12): 1177 - 1182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Steward, M. S. Lever, A. J. H. Simpson, A. M. Sefton, and T. J. G. Brooks Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones J. Antimicrob. Chemother., July 1, 2004; 54(1): 95 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. V. Inglesby, D. T. Dennis, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. D. Fine, A. M. Friedlander, J. Hauer, J. F. Koerner, et al. Plague as a Biological Weapon: Medical and Public Health Management JAMA, May 3, 2000; 283(17): 2281 - 2290. [Abstract] [Full Text] [PDF]
|
|